Ropes Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

Ropes Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$6.9K	Hold	772	–	–	﹤0.01%	252
2023 Q2	$6.66K	Sell	772 -386	-33%	-$4.12K	﹤0.01%	274
2023 Q1	$12.2K	Hold	1,158	–	–	﹤0.01%	260
2022 Q4	$39.3K	Hold	1,158	–	–	0.01%	267
2022 Q3	$56K	Hold	1,158	–	–	0.01%	252
2022 Q2	$66K	Hold	1,158	–	–	0.01%	264
2022 Q1	$94K	Hold	1,158	–	–	0.02%	285
2021 Q4	$235K	Hold	1,158	–	–	0.04%	246
2021 Q3	$312K	Hold	1,158	–	–	0.05%	225
2021 Q2	$298K	Sell	1,158 -386	-25%	-$107K	0.05%	223
2021 Q1	$447K	Hold	1,544	–	–	0.08%	172
2020 Q4	$394K	Hold	1,544	–	–	0.06%	172
2020 Q3	$384K	Buy	1,544 +1,543	+154,300%	+$485K	0.07%	159
2020 Q2	$0	Buy	+1	New	+$312	﹤0.01%	597

Other funds holding NKTR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Ropes Wealth Advisors's NKTR Position: Q3 2023 in Review

Ropes Wealth Advisors held its Nektar Therapeutics (NKTR) position steady in Q3 2023 at 772 shares worth $6.9K. The position accounts for ﹤0.01% of the portfolio, ranked #252.

Ropes Wealth Advisors first reported a position in NKTR in Q2 2020 and has held it in 14 quarters since. The position peaked at $447K in Q1 2021. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

Ropes Wealth Advisors held 772 shares of Nektar Therapeutics worth $6.9K as of Q3 2023.
Ropes Wealth Advisors left its Nektar Therapeutics share count unchanged in Q3 2023.
Nektar Therapeutics made up ﹤0.01% of Ropes Wealth Advisors's portfolio in Q3 2023, its #252 holding.
Ropes Wealth Advisors first reported a position in Nektar Therapeutics in Q2 2020 and has held it in 14 quarters since.
Ropes Wealth Advisors's Nektar Therapeutics position peaked at $447K in Q1 2021.
138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Ropes Wealth Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.